Overview

The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer

Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 study to investigate NC318 alone or in combination with Pembrolizumab in patients with advanced non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Yale University
Collaborators:
Merck Sharp & Dohme Corp.
National Cancer Institute (NCI)
NextCure, Inc.
Treatments:
Pembrolizumab